Tesamorelin Peptide – 2 mg / 10mg / 20mg
Purity: 99.66% / 99.651% / 99.328%
Product Information
- Common Name: Tesamorelin
- CAS Number: 218949-48-5
- Content: 2.41mg Tesamorelin peptide
- Content: 9.83mg Tesamorelin peptide
- Content: 22.21mg Tesamorelin peptide
- Packaging: Sealed under vacuum or filled with inert gas to preserve stability
Physical Characteristics
- Form: White to off-white lyophilized powder
- Solution Colour: Clear after reconstitution
Solubility
- Water soluble
- Commonly reconstituted with sterile water
Storage Recommendations
- Store away from direct sunlight and UV exposure
- Long-term storage: Freezer recommended
- Short-term storage: Refrigerator
- Avoid repeated freeze–thaw cycles
- Once reconstituted: refrigerate only and do not freeze
Mixing Reference
2mg
- 1 ml sterile water = 10 × 0.1 ml portions (0.2 mg per 0.1 ml)
- 2 ml sterile water = 20 × 0.1 ml portions (0.1 mg per 0.1 ml)
- Measurement reference:
- 1 mg = 1,000 mcg
10mg
- 1 ml sterile water = 10 × 0.1 ml portions (1 mg per 0.1 ml)
- 2 ml sterile water = 20 × 0.1 ml portions (0.5 mg per 0.1 ml)
- Measurement reference:
- 1 mg = 1,000 mcg
20mg
- • 1 ml sterile water = 20 × 0.1 ml portions (2 mg per 0.1 ml)
• 2 ml sterile water = 40 × 0.1 ml portions (1 mg per 0.1 ml) - Measurement reference:
- 1 mg = 1,000 mcg
Disclaimer
This product is not:
- Intended to diagnose, treat, cure, or prevent any disease
- A dietary or sports supplement
- Approved for human use
- An injectable medication
For research and laboratory use only.
| Tesamorelin | Tesamorelin is a synthetic peptide that mimics the natural Growth Hormone-Releasing Hormone. It stimulates the Pituitary Gland to release Human Growth Hormone, which in turn increases Insulin-like Growth Factor 1. Tesamorelin is primarily studied for fat reduction and body composition improvement, especially in populations affected by lipodystrophy. 1. HIV-Associated Lipodystrophy Tesamorelin was originally developed to treat HIV-associated lipodystrophy: stimulates GH release to reduce visceral abdominal fat improves body composition without significant loss of lean mass clinical trials show reduction in central adiposity in HIV patients This led to FDA approval for this specific indication. 2. Growth Hormone Deficiency and Metabolic Research Because Tesamorelin increases GH and IGF-1, researchers also study it in contexts of: age-related decline in GH (Somatopause) potential improvements in body composition, lean mass, and fat metabolism metabolic health improvements in individuals with abdominal obesity 3. Lipid and Cardiovascular Effects Studies suggest Tesamorelin may positively affect: triglyceride levels total cholesterol and LDL waist-to-hip ratio This research focuses on reducing cardiovascular risk associated with visceral fat. 4. Liver Fat Reduction Tesamorelin has been studied in non-alcoholic fatty liver disease (NAFLD): reduces liver fat accumulation may improve liver enzyme profiles potential therapeutic role for metabolic liver conditions 5. Anti-Aging and Body Composition Research Outside of HIV-specific research, Tesamorelin is being explored for: reducing abdominal obesity in aging populations enhancing lean muscle mass improving insulin sensitivity and metabolic function These effects are largely experimental and studied in clinical trials. ✅ Important notes Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. Its main mechanism is stimulation of endogenous GH release rather than direct GH injection. Common side effects include joint pain, swelling, and injection-site reactions. Effects are more targeted on fat distribution than general GH therapy. |
|---|
Only logged in customers who have purchased this product may leave a review.
Related products
Featured Product
Growth Hormone Support Research
Growth Hormone Support Research
Featured Product
Featured Product
Growth Hormone Support Research
Home
Reviews
There are no reviews yet.